NEWPORT BEACH, Calif., Oct. 07, 2022 (GLOBE NEWSWIRE) — CLS Americas, a subsidiary of Clinical Laserthermia Systems AB, at present introduced it should exhibit its TRANBERG™ Thermal Therapy System on the Unio Health Partners Summit being held October 6-8, 2022 on the Renaissance Newport Beach Hotel, Newport, CA. The TRANBERG™ System is designed to offer exact and correct prostate tumor ablation in a minimally invasive, outpatient setting. Compared to different focal therapies, focal laser ablation has demonstrated larger ranges of precision and accuracy with decrease threat of unintended effects, reminiscent of erectile dysfunction and urinary incontinence.
“We’re excited to introduce our office-based TRANBERG focal laser ablation system to the urologists and providers at the Unio Health Partners Summit,” stated Michael Magnani, president of CLS Americas. “Unio provides best-in-class clinical programs and ancillary services to its affiliates. It’s a great opportunity for us to partner with them for the summit.”
TRANBERG™ Thermal Therapy System
The TRANBERG™ Thermal Therapy System may be configured for MR/US fusion-guided procedures utilizing real-time tissue temperature measurements for exact remedy and ablation management. It features a desk-top cellular laser unit, revolutionary non-cooled laser applicators, tissue temperature probes, and procedure-specific equipment. The TRANBERG system may be deployed in both a transperineal or transrectal strategy.
About CLS and the TRANBERG® Product Portfolio
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG® Thermal Therapy Systems, together with ThermoguideTM Workstation and sterile disposables, for minimally invasive laser ablation of soppy tissue, most cancers tumors and drug-resistant epilepsy, in accordance with regulatory approvals within the EU and the US. CLS goals at increasing the present approvals to additionally embody therapy with imILT®, the Company’s interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal therapy impact. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market below the image CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: [email protected].
For extra details about CLS, please go to the Company’s web site for the US market: www.clinicallaser.com/en.
